TrialEuropean urology focus2019

Phase III Trial of Intravenous Mannitol Versus Placebo During Nephron-sparing Surgery: Post Hoc Analysis of 3-yr Outcomes.

Nathan C Wong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.